These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 23542173)

  • 21. Targeting the HER-kinase axis in cancer.
    Gross ME; Shazer RL; Agus DB
    Semin Oncol; 2004 Feb; 31(1 Suppl 3):9-20. PubMed ID: 15052539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.
    Liu X; Wang Q; Yang G; Marando C; Koblish HK; Hall LM; Fridman JS; Behshad E; Wynn R; Li Y; Boer J; Diamond S; He C; Xu M; Zhuo J; Yao W; Newton RC; Scherle PA
    Clin Cancer Res; 2011 Nov; 17(22):7127-38. PubMed ID: 21918175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging paradigms and recent progress in targeting ErbB in cancers.
    Stoup N; Liberelle M; Leb├Ęgue N; Van Seuningen I
    Trends Pharmacol Sci; 2024 Jun; 45(6):552-576. PubMed ID: 38797570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
    Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
    Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
    Huang F; Greer A; Hurlburt W; Han X; Hafezi R; Wittenberg GM; Reeves K; Chen J; Robinson D; Li A; Lee FY; Gottardis MM; Clark E; Helman L; Attar RM; Dongre A; Carboni JM
    Cancer Res; 2009 Jan; 69(1):161-70. PubMed ID: 19117999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics.
    Mitchell RA; Luwor RB; Burgess AW
    Exp Cell Res; 2018 Oct; 371(1):1-19. PubMed ID: 30098332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
    Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
    Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
    Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
    Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
    Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
    Kalman B; Szep E; Garzuly F; Post DE
    Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.
    Lee JM; Lee SH; Hwang JW; Oh SJ; Kim B; Jung S; Shim SH; Lin PW; Lee SB; Cho MY; Koh YJ; Kim SY; Ahn S; Lee J; Kim KM; Cheong KH; Choi J; Kim KA
    Oncogene; 2016 Aug; 35(34):4437-46. PubMed ID: 26853467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.
    Sheng Q; Liu J
    Br J Cancer; 2011 Apr; 104(8):1241-5. PubMed ID: 21364581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
    Brechbiel J; Miller-Moslin K; Adjei AA
    Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
    Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.
    Rexer BN; Arteaga CL
    Crit Rev Oncog; 2012; 17(1):1-16. PubMed ID: 22471661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.
    Yamaoka T; Ohba M; Ohmori T
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29140271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.